FDA Approves Revolutionary Blood Cancer Drug with BMS Blockbuster Potential

Source: Business Insider

Dec 02, 2015

The FDA has approved Bristol-Myers Squibb's Empliciti to treat multiple myeloma, to be used in combination with two other FDA-approved treatments, dexamethasone and Celgene's Revlimid.

In Empliciti's 646-participant clinical trial, patients treated with the three-drug cocktail took longer to relapse and had a higher chance of tumor shrinkage than those treated with the traditional two-drug therapy.

"Empliciti represents a fundamentally different approach of directly activating the immune system in patients with relapsed or refractory multiple myeloma, delivering improved outcomes for those in need," a BMS spokeswoman told Business Insider.

Bristol-Myers and AbbVie are codeveloping Empliciti, which will be marketed under the BMS name.

The monthly cost of Empliciti for biweekly doses is about $10,000. Including the two-month induction period, the first-year cost of the drug is approximately $142,000.

Read the Business Insider article

Make sure you didn't miss anything - view our monthly news recap

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments